ClinicalTrials.gg
TerminatedNCT06570772Updated Dec 26, 2025

Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio

A Phase 3 interventional study of AVT16 and Vedolizumab in Ulcerative Colitis, sponsored by Alvotech Swiss AG. Terminated at 100 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Alvotech Swiss AG · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
The study has been terminated based on Sponsor decision. This decision is not related to any safety concerns associated with the investigational products. It is related to the fact that study will be not required for product dossier submission.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 221 studies in Colitis, Ulcerative with a site in Poland — 36 open to participants now, 65 under way, 31 of them phase 3. Colitis, Ulcerative · Poland.

Enrollment
74th of 215
301 · median 196
Started
2024
with 14 others
Phase 3
83 of 221
13 open now
Registered
185th of 221
by date

Among the 221 studies in Colitis, Ulcerative with a site in Poland, this one is the 74th largest by enrollment of the 215 interventional ones that give a count, is one of 15 that started in 2024, is one of 83 in phase 3, and was the 185th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

36 of the 221 studies in Colitis, Ulcerative with a site in Poland are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies in Colitis, Ulcerative with a site in Poland, or all of them as a file.
02

Study summary

The study has been designed as a randomised, parallel-group, double-blind, 2 arm study of the comparative efficacy, safety and immunogenicity of AVT16 and Entyvio in male and female subjects with moderate to severe active ulcerative colitis.

Read the detailed description

The study will consist of a screening period, a treatment and assessment period and an End of Study visit. Eligibility for the study will be determined during a screening period. Subjects who meet the eligibility criteria will be randomised to either AVT16 or Entyvio.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed
  • Male and female subjects from 18 to 80 years of age
  • Diagnosis of Ulcerative Colitis

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Crohn's colitis
  • Extensive colonic resection
  • Active or latent tuberculosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
301 participants (actual)

Study arms

  • Experimental
    AVT16

    Experimental Arm AVT16 300mg iv is the proposed biosimilar for Entyvio (vedolizumab)

    Biological: AVT16

  • Active comparator
    Entyvio

    Entyvio (vedolizumab) 300mg iv is the proposed active comparator for AVT16

    Biological: Vedolizumab

Interventions

  • BiologicalAVT16

    AVT16 will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46

    Also known as: AVT16 proposed biosimilar to vedolizumab

  • BiologicalVedolizumab

    Entyvio (vedolizumab) will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46

    Also known as: Entyvio

06

What researchers measure

Primary outcomes

  1. Clinical Response at week 6

    Change in Mayo Score/Disease Activity for Ulcerative Colitis. Scale 0-12, higher score - worse outcome

    Time frame: Week 6

Secondary outcomes

  1. Clinical Response at week 52

    Change in Mayo Score/Disease Activity for Ulcerative Colitis. Scale 0-12, higher score - worse outcome

    Time frame: Week 52

07

Study locations

100 sites
  • Investigational Site 161704
    Ciudad Autónoma de BuenosAires, Argentina
  • Investigational Site 161702
    Córdoba, Argentina
  • Investigational Site 161701
    Quilmes, Argentina
  • Investigational Site 161705
    San Miguel de Tucumán, Argentina
  • Investigational Site 160111
    Burgas, Bulgaria
  • Investigational Site 160102
    Pleven, Bulgaria
  • Investigational Site 160109
    Rousse, Bulgaria
  • Investigational Site 160101
    Sliven, Bulgaria
  • Investigational Site 160103
    Sofia, Bulgaria
  • Investigational Site 160105
    Sofia, Bulgaria
  • Investigational Site 160108
    Sofia, Bulgaria
  • Investigational Site 160107
    Stara Zagora, Bulgaria
  • Investigational Site 160106
    Vratsa, Bulgaria
  • Investigational Site 160204
    Bjelovar, Croatia
  • Investigational Site 160202
    Osijek, Croatia
  • Investigational Site 160205
    Rijeka, Croatia
  • Investigational Site 160206
    Slavonski Brod, Croatia
  • Investigational Site 160202
    Zagreb, Croatia
  • Investigational Site 160207
    Zagreb, Croatia
  • Investigational Site 160507
    Batumi, 6010, Georgia
  • Investigational Site 160501
    Tbilisi, Georgia
  • Investigational Site 160502
    Tbilisi, Georgia
  • Investigational Site 160503
    Tbilisi, Georgia
  • Investigational Site 160505
    Tbilisi, Georgia
  • Investigational Site 160506
    Tbilisi, Georgia
  • Investigational Site 160802
    Liepāja, Latvia
  • Investigational Site 160801
    Riga, Latvia
  • Investigational Site 160803
    Riga, Latvia
  • Investigational Site 161025
    Bydgoszcz, Poland
  • Investigational Site 161008
    Chojnice, Poland
  • Investigational Site 161013
    Grudziądz, Poland
  • Investigational Site 161029
    Kielce, Poland
  • Investigational Site 161018
    Knurów, Poland
  • Investigational Site 161035
    Krakow, Poland
  • Investigational Site 1614011
    Ksawerów, Poland
  • Investigational Site 161028
    Kłodzko, Poland
  • Investigational Site 161037
    Lodz, Poland
  • Investigational Site 161015
    Lublin, Poland
  • Investigational Site 161033
    Olsztyn, Poland
  • Investigational Site 161021
    Piotrkow Trybunalski, Poland
  • Investigational Site 161022
    Poznan, Poland
  • Investigational Site 161023
    Rzeszów, Poland
  • Investigational Site 161024
    Rzeszów, Poland
  • Investigational Site 161009
    Sopot, Poland
  • Investigational Site 161014
    Swidnica, Poland
  • Investigational Site 161010
    Szczecin, Poland
  • Investigational Site 161005
    Torun, Poland
  • Investigational Site 161017
    Tychy, Poland
  • Investigational Site 161007
    Warsaw, Poland
  • Investigational Site 161012
    Warsaw, Poland
  • Investigational Site 161016
    Warsaw, Poland
  • Investigational Site 161041
    Warsaw, Poland
  • Investigational Site 161006
    Wroclaw, Poland
  • Investigational Site 161040
    Wroclaw, Poland
  • Investigational Site 161026
    Zamość, Poland
  • Investigational Site 161102
    Constanța, Romania
  • Investigational Site 161103
    Târgu Mureş, Romania
  • Investigational Site 161101
    Timișoara, Romania
  • Investigational Site 161201
    Belgrade, Serbia
  • Investigational Site 161203
    Belgrade, Serbia
  • Investigational Site 161204
    Belgrade, Serbia
  • Investigational Site 161206
    Belgrade, Serbia
  • Investigational Site 161209
    Belgrade, Serbia
  • Investigational Site 161205
    Leskovac, Serbia
  • Investigational Site 161211
    Niš, Serbia
  • Investigational Site 161207
    Novi Sad, Serbia
  • Investigational Site 161202
    Pančevo, Serbia
  • Investigational Site 161208
    Zrenjanin, Serbia
  • Investigational Site 161304
    Banská Bystrica, Slovakia
  • Investigational Site 161303
    Bratislava, Slovakia
  • Investigational Site 161301
    Košice, Slovakia
  • Investigational Site 161302
    Prešov, Slovakia
  • Investigational Site 161305
    Rimavská Sobota, Slovakia
  • Investigational Site 161306
    Trnava, Slovakia
  • Investigational Site 162204
    Colombo, Sri Lanka
  • Investigational Site 162203
    Galle, Sri Lanka
  • Investigational Site 162206
    Jaffna, Sri Lanka
  • Investigational Site 162205
    Kandy, Sri Lanka
  • Investigational Site 162201
    Ragama, Sri Lanka
  • Investigational Site 160411
    Cherkasy, Ukraine
  • Investigational Site 160401
    Chernivtsi, Ukraine
  • Investigational Site 160412
    Ivano-Frankivsk, Ukraine
  • Investigational Site 160404
    Kyiv, Ukraine
  • Investigational Site 160405
    Kyiv, Ukraine
  • Investigational Site 160406
    Kyiv, Ukraine
  • Investigational Site 160413
    Kyiv, Ukraine
  • Investigational Site 160416
    Kyiv, Ukraine
  • Investigational Site 160420
    Kyiv, Ukraine
  • Investigational Site 160422
    Kyiv, Ukraine
  • Investigational Site 160425
    Kyiv, Ukraine
  • Investigational Site 160407
    Lviv, Ukraine
  • Investigational Site 160409
    Lviv, Ukraine
  • Investigational Site 160417
    Lviv, Ukraine
  • Investigational Site 160408
    Uzhhorod, Ukraine
  • Investigational Site 160403
    Vinnytsia, Ukraine
  • Investigational Site 160410
    Vinnytsia, Ukraine
  • Investigational Site 160415
    Vinnytsia, Ukraine
  • Investigational Site 160421
    Vinnytsia, Ukraine
  • Investigational Site 160424
    Vinnytsia, Ukraine
  • Investigational Site 160419
    Zhytomyr, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Nov 2025, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Aug 26, 2024
StartActual
Sep 23, 2024
Primary completionActual
Nov 25, 2025
CompletionActual
Nov 25, 2025
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06570772
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Sep 23, 2024
Primary completion
Nov 25, 2025
Completion
Nov 25, 2025
Last update
Dec 26, 2025

Study contacts

Eveline Schurink
study director · Alvotech Swiss AG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion